| Attributes | Values |
|---|
| rdf:type
| |
| http://linked.open...gbank/description
| - Lutropin alfa is a recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues. It is a heterodimeric glycoprotein. Each monomeric unit is a glycoprotein molecule. In females, an acute rise of LH ("LH surge") triggers ovulation and the development of the corpus luteum. In males, it stimulates Leydig cell production of testosterone. Lutropin alfa was the first and only recombinant human form of luteinizing hormone (LH) developed for use in the stimulation of follicular development. (en)
|
| http://linked.open...y/drugbank/dosage
| |
| http://linked.open...generalReferences
| - # Blanchard J: Gastrointestinal absorption. I. Mechanisms. Am J Pharm Sci Support Public Health. 1975 Sep-Oct;147(5):135-46. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3972 # Louvet JP, Harman SM, Ross GT: Effects of human chorionic gonadotropin, human interstitial cell stimulating hormone and human follicle-stimulating hormone on ovarian weights in estrogen-primed hypophysectomized immature female rats. Endocrinology. 1975 May;96(5):1179-86. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1122882 # Nielsen MS, Barton SD, Hatasaka HH, Stanford JB: Comparison of several one-step home urinary luteinizing hormone detection test kits to OvuQuick. Fertil Steril. 2001 Aug;76(2):384-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11476792 # Gibreel A, Bhattacharya S: Recombinant follitropin alfa/lutropin alfa in fertility treatment. Biologics. 2010 Feb 4;4:5-17. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20161981 # Dhillon S, Keating GM: Lutropin alfa. Drugs. 2008;68(11):1529-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18627209 #Lutropin Alfa. In DynaMed [database online]. EBSCO Information Services. http://search.ebscohost.com/login.aspx?direct=true&site=DynaMed&id=233015. Updated January 18, 2013. Accessed October 1, 2014. #Lexicomp. Lutropin alfa. N.p., 2014. Web. 11 Nov. 2014. #EMD Serono, A Division of EMD Inc., Canada. Lutropin Alfa. Mississauga, Ontario: N.p., 2012. (en)
|
| http://linked.open...gy/drugbank/group
| |
| http://linked.open...drugbank/halfLife
| - Biphasic; terminal half-life is approximately 18 hours. (en)
|
| http://linked.open...ugbank/indication
| - For treatment of infertility in women with hypothalamic or pituitary insufficiency (hypogonadotropic hypogonadism) and profound LH deficiency (LH <1.2 international units [IU]/L) (en)
|
| http://linked.open...bank/manufacturer
| |
| sameAs
| |
| Title
| |
| adms:identifier
| |
| http://linked.open...mechanismOfAction
| - Luteinizing hormone binds to a receptor shared with the human chorionic gonadotropin hormone (hCG) on the ovarian theca (and granulosa) cells and testicular Leydig cells. This LH/CG transmembrane receptor is a member of the super-family of G protein-coupled receptors. Adenylate cyclase then activates many other pathways leading to steroid hormone production and other follicle maturation processes. (en)
|
| http://linked.open...drugbank/packager
| |
| http://linked.open...y/drugbank/patent
| |
| http://linked.open...outeOfElimination
| - Total body clearance is approximately 2 to 3 L/h with less than 5 percent of the dose being excreted unchanged renally. (en)
|
| http://linked.open.../drugbank/synonym
| - LH-B (en)
- LSH- beta (en)
- LSH-B (en)
- Luteinizing hormone beta subunit (en)
- Lutropin beta chain precursor (en)
- Luteinizing hormone (en)
- ICSH (en)
- Insterstiial cell-stimulating hormone (en)
- LH (en)
- Lutrophin (en)
- Lutropin alpha (en)
|
| http://linked.open...drugbank/toxicity
| - Lutropin alfa is not indicated for people under 16 and over 60, pregnant and lactating women, patients with uncontrolled thyroid and adrenal failure, patients with active, untreated tumours of the hypothalamus and pituitary gland, and in any patient with a condition that makes a normal pregnancy possible such as primary ovarian failure or fibroid tumors of the uterus. (en)
|
| http://linked.open...umeOfDistribution
| - The steady state volume of distribution is around 10-14 L. (en)
|
| http://linked.open.../drug/hasAHFSCode
| |
| foaf:page
| |
| http://linked.open...Molecular-Formula
| |
| http://linked.open.../Molecular-Weight
| |
| http://linked.open...l/drug/hasATCCode
| |
| http://linked.open...ugbank/absorption
| - Mean absolute bioavailability is 56%, following sub-Q administration, maximum serum concentrations reached after 4–16 hours. Time to peak, serum: 9 hours (en)
|
| http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
| http://linked.open...casRegistryNumber
| |
| http://linked.open...drugbank/category
| |
| http://linked.open...rugbank/clearance
| - * 2 – 3 L/h [healthy female following subcutaneous administration] (en)
|
| http://linked.open...gbank/containedIn
| |
| http://linked.open...nk/Hydrophobicity
| |
| http://linked.open...Isoelectric-Point
| |
| http://linked.open...ank/Melting-Point
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)